Oramed Pharmaceuticals (ORMP) Given Media Impact Score of 0.24
Media coverage about Oramed Pharmaceuticals (NASDAQ:ORMP) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.4688992271931 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded down 0.20% during mid-day trading on Tuesday, hitting $9.92. The stock had a trading volume of 26,047 shares. Oramed Pharmaceuticals has a one year low of $5.70 and a one year high of $11.34. The company’s market cap is $132.13 million. The firm’s 50 day moving average price is $10.22 and its 200-day moving average price is $8.57.
A number of brokerages have recently issued reports on ORMP. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a research report on Thursday, October 5th. ValuEngine raised Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th.
COPYRIGHT VIOLATION WARNING: This news story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/10/31/oramed-pharmaceuticals-ormp-given-media-impact-score-of-0-24.html.
In related news, Director Xiaopeng Li acquired 89,636 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $8.50 per share, with a total value of $761,906.00. Following the completion of the transaction, the director now owns 206,350 shares of the company’s stock, valued at $1,753,975. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 27.50% of the stock is currently owned by corporate insiders.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.